Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment

Fibromyalgia Clinical Trial

Official title:

Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01266733
• Other study ID #: 2006111057
• Status: Completed
• Phase: Phase 2
• First received: December 23, 2010
• Last updated: June 17, 2015
• Start date: February 2007
• Est. completion date: February 2010

Study information

• Verified date: December 2010
• Source: Hospital Galdakao-Usansolo
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentSpain: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess improvement in health related quality of life of fibromyalgia patients following 6 weeks of interdisciplinary treatment compared to the usual treatment.

Description:

Fibromyalgia (FM) is the most common cause of diffuse pain in the bones and joints, with a prevalence in general adult populations estimated at between 0.7% and 3.3%. In Spain, the prevalence of FM is 2-3%; it affects mainly women, with new diagnoses peaking between the ages of 40 and 49 years. In certain populations, however, the prevalence may be much higher, as in 15% of patients referred from internal medicine units or 12% of patients referred to rheumatology specialists in Spain.

Fibromyalgia produces various degrees of disability and pain. It also has a clear impact on health-related quality of life (HRQoL). Burckhardt et al. observed lower HRQoL among patients with fibromyalgia than among healthy subjects. Indeed, the HRQoL for those with FM was similar to that of patients with insulin-dependent diabetes mellitus or chronic obstructive pulmonary disease. Among patients with non-cancer chronic pain referred to the pain management unit at our institution, those with bone and joint pain and with FM had the worst progress 6 months after diagnosis as measured by HRQoL.

The characteristics of FM, such as its complex and unknown etiology, wide range of symptoms and signs, and multiple comorbidities make identifying effective therapies particularly difficult. As a result, no consensus yet exists regarding the best therapeutic approaches, and treatment of FM presents a challenge for clinicians. Clinical research suggests that pharmacologic treatment alone is not the best approach for FM, and that an integrated biopsychosocial approach that includes non-pharmacologic therapies along with pharmacologic therapies improves outcomes in these patients.

In our hospital, between 5% and 10% of patients newly diagnosed with FM are referred to the pain management unit. We established a clinical trial in this population to assess improvement in HRQoL following 6 months of interdisciplinary treatment compared to the usual treatment, as well as to identify predictors for improvement in HRQoL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 153
• Est. completion date: February 2010
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• a patient must have been diagnosed with FM according to diagnostic criteria of the American College of Rheumatology

• being 18 years or older and

• having had continuous chronic pain for at least 6 months.

Exclusion Criteria:

• Patients were excluded if they did not agree to participate in the study,

• were suffering from a severe psychiatric or organic disorder, or

• were involved in employment-related legal proceedings related to their FM. Participants in the trial were required to sign an informed consent form.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Behavioral:
• Interdisciplinary treatment
The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
• Interdisciplinary treatment of fibromyalgia
The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.

Locations

Country	Name	City	State
Spain	Hospital Galdakao-Usansolo	Galdakao	Bizkaia

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Galdakao-Usansolo

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health-related quality of life among patients with fibromyalgia (FIQ: Fibromyalgia Impact Questionnaire)	Fibromyalgia patients completed the FIQ at baseline and again 6 months after the interdisciplinary intervention.	6 months	No
Secondary	Anxiety and depressive symptoms (HADS: The Hospital Anxiety and Depression Scale)	Patients with fibromyalgia completed the HADS at baseline and again 6 months after the intervention	6 months	No